NewsNovo
The GLP-1 weight-loss drug boom was supposed to shrink the aesthetics market.
A Swiss aesthetics firm says it is doing the opposite, arguing that patients using drugs like Ozempic develop facial volume loss and are already driving demand for treatments including Botox.
The company calls the condition "Ozempic face" and expects further GLP-1 adoption to accelerate that demand.
How weight-loss drugs create a treatment pipeline When patients lose weight rapidly through GLP-1 drugs, fat leaves the face along with the body. The Swiss firm calls this the "sagging face" effect.
Keep reading